Clinical trial · Observational
The Pathogenesis and Prognostic Factors of Lymphoma
NCT06203652CI-TRIAL-00072950recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to describe the clinical and genetic characteristics of Chinese lymphoma patients, and to explore the relationship between those characteristics and phatogenesis.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hodgkin Lymphoma | Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Non-hodgkin Lymphoma | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Real-world regimen | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- All enrolled patients
- description
- All patients who are eligible for participation to the study.
- interventionNames
- Other: Real-world regimen
Primary outcomes (1)
- measure
- OS
- timeFrame
- Baseline up to data cut-off (Up to approximately 20 years)
- description
- Overall survival (OS) refers to the time from receiving the first dose to death from any cause
Secondary outcomes (1)
- measure
- PFS
- timeFrame
- Baseline up to data cut-off (Up to approximately 20 years)
- description
- Progression-free survival (PFS) is defined as the time from the date of first administration to the date of first disease progression or death from any cause, whichever occurs first.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients with pathological diagnosis of lymphoma (including Hodgkin lymphoma and non-Hodgkin lyphoma, eg. THRLBCL, DLBCL, MZL, CLL/SLL...) from 2007 to 2027. * Patients with complete diagnostic, treatment and follow-up records. * Fully comprehension and signature of the informed consent form (ICF) for participation. Exclusion Criteria: * Those who refuse to use reliable methods of contraception during pregnancy, lactation or age-appropriate period. * Severe mental illness. * Patients deemed unsuitable for inclusion by the investigator.
References
Publications (0)
Data not yet available
No reference posted for this study.